RALEIGH, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc., (Nasdaq: BDSI) announced that the company continues to anticipate a resubmission containing the Risk Evaluation and Mitigation Strategy (REMS) for its lead product ONSOLIS™ to the Food and Drug Administration (FDA) in December following a meeting with the FDA this week.
